United Laboratories International Holdings Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	14yrs

Recente managementupdates

Recent updates

CEO

United Laboratories International Holdings heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hoi Shan Tsoi	Executive Chairman	15.6yrs	CN¥4.20m	0.91% HK$ 170.3m
Wing Hon Leung	Vice Chairman	18yrs	CN¥4.17m	0.0086% HK$ 1.6m
Su Yan Zhu	VP & Executive Director	14yrs	CN¥2.52m	0.0034% HK$ 645.1k
Xian Hong Zou	VP & Executive Director	14yrs	CN¥2.52m	0.014% HK$ 2.7m
Siu Chit Choy	Global Director of Intermediate & Bulk Medicine and Executive Director	11.4yrs	CN¥2.80m	0.011% HK$ 2.1m
Yu Ping Fang	VP & Executive Director	14yrs	CN¥2.55m	0.0034% HK$ 643.2k
Ming Song	Independent Non-Executive Director	17.5yrs	CN¥234.00k	geen gegevens
Peng Oon Chong	Independent Non-Executive Director	15.7yrs	CN¥234.00k	geen gegevens
Qiushi Fu	Independent Non-Executive Director	1.4yrs	CN¥118.00k	geen gegevens

14.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 3933 zijn ervaren en ervaren (gemiddelde ambtstermijn van 14 jaar).

United Laboratories International Holdings Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

Less than half of directors are independent

Less than half of directors are independent

Recent updates

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings released: EPS: CN¥0.82 (vs CN¥0.71 in 1H 2023)

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

The United Laboratories International Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥1.49 (vs CN¥0.87 in FY 2022)

Investor sentiment improves as stock rises 16%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Less than half of directors are independent

New minor risk - Share price stability

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

Investor sentiment deteriorates as stock falls 17%

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Investor sentiment improves as stock rises 19%

Full year 2022 earnings released: EPS: CN¥0.87 (vs CN¥0.54 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

The United Laboratories International Holdings Limited Announces Approval of Marketing of Sodium Hyaluronate Eye Drops Applied by Zhuhai United Laboratories Co., Ltd

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 181,757,450 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2022.

The United Laboratories International Holdings Limited Announces an Interim Dividend for the Year 2022, Payable on 6 October 2022

The United Laboratories International Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022

First half 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.34 in 1H 2021)

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2021, Payable on 20 July 2022

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.40 in FY 2020)

Less than half of directors are independent

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 184,039,050 shares, representing 10% of its issued share capital, under the authorization approved on June 22, 2021.

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

The United Laboratories International Holdings Limited Announces Updated Information of the Group's Products

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

The United Laboratories International Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day low: HK$5.12

New 90-day low: HK$5.40

New 90-day low: HK$5.70

New 90-day low: HK$6.40

New 90-day low: HK$6.82

First half earnings released

Earnings released

New 90-day high - HK$8.66

The United Laboratories International Holdings Limited to Report First Half, 2020 Results on Aug 25, 2020

CEO

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd